There will be no pressure on authorities to approve the vaccine, and the final call for the approval of emergency use will be focused on scientific principles.
Dr V K Paul, Member, NITI Aayog, reassured India that it is fully prepared for the vaccination initiative and at the vaccination threshold.
Addressing the session on Vaccine Magic and Reimagining Healthcare in a Post-COVID environment, organised during FICCI’s 93rd Annual Convention, Dr. Paul said ‘’There will be no pressure on the COVID-19 vaccine approval drug regulator and the final call will be made on scientific principles to allow its emergency use approval."
He confirmed that 33 vaccines are in the clinical trial process worldwide, out of which 10 are in the advanced trial phase. Among the top 10 global players, 3 Indian vaccines are included. It’s a proud moment to say that the three major indigenous players-Bharat Biotech-ICMR, Zydus Cadila and Serum Institute-AstraZeneca-are in clearance phase-2, which produced an Apollo 11 moment for India. This gives us hope for manufacturing the vaccines not just for India but also for the world.
He also noted that access to the population at risk of mortality and safety of our healthcare system and the COVID-19 response system was the main factor when prioritising the population for vaccine inoculation.
He urged FICCI to collaborate with the state government to increase healthcare expenditure, increase healthcare human capital by optimising private sector training, bridge the enormous gap in healthcare infrastructure, and develop institutions for optimal disease control and data management systems. He also encouraged the sector to work towards developing the country’s capacity for mental health. He also called for greater involvement by the private sector in ramping up health infrastructure.
For more information on this article read from source: https://www.expresshealthcare.in/amp/news/3-indian-vaccines-in-phase-2-has-created-apollo-11-moment-for-india-dr-v-k-paul/426314/